

Racial differences in prostate tumor microenvironment: implications for disparate clinical outcomes and potential opportunities

Sandeep Goswami^{1,2} Chandrani Sarkar^{1,2,3}, Seema Singh^{1,2,3} Ajay Pratap Singh^{1,2,3} Debanjan Chakroborty^{1,2,3}

¹ Department of Pathology, University of South Alabama, Mobile, Alabama, USA.

² Cancer Biology Program, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama, USA.

³ Department of Biochemistry and Molecular Biology, University of South Alabama, Mobile, Alabama, USA.

*Corresponding author: Debanjan Chakroborty, Email: dchakroborty@southalabama.edu,

ABSTRACT

Disparities in cancer incidence and outcome are common among the racial and ethnical minorities in the United States and are of significant social and clinical concern. Prostate cancer is the most commonly diagnosed non-cutaneous malignancy in American men and exhibits substantial racial disparities with African American men bearing the highest burden in terms of incidence and mortality. A multitude of factors, including socioeconomic, behavioral, and access to healthcare, have been implicated as the underlying causes of such disparities. More recent data also suggest that there are inherent molecular and biological differences in prostate tumors of patients having distinct racial backgrounds. Tumor microenvironment has tremendous impact on the course of cancer progression and clinical outcome and may also contribute to the racial disparities observed in prostate cancer. Therefore, a better understanding of critical differences in the tumor microenvironment components may provide newer directions to study the biological causes of prostate cancer health disparities and may identify novel therapeutic targets. This review discusses the findings related to the tumor microenvironment differences between African American and Caucasian American prostate cancer patients and makes suggestion regarding their potential significance in prostate cancer disparities.

KEYWORDS: Prostate cancer, racial disparity, tumor microenvironment

Citation: Goswami S et al (2022) Racial differences in prostate tumor microenvironment: implications for disparate clinical outcomes and potential opportunities. *Cancer Health Disparities*. doi:10.9777/chd.2022.1003

1.0. Introduction

Prostate cancer (PCa) is the most commonly diagnosed non-cutaneous malignancy and the second leading cause of cancer-related death in American men [1, 2]. Among all the cancers, PCa not only shows extreme variations in its potential to cause morbidity and death in men but also displays great variations in geographic and racial distribution [1, 2, 3, 4]. In the United States, despite significant improvements in cancer diagnosis and treatment strategies, African American (AA) men suffer disproportionately from PCa with over 80% higher incidence rates than men of European American (CA, Caucasian American) origin [5, 6, 7, 8]. AA men are also more likely to be diagnosed at a younger age and present with more advanced and aggressive disease stages [8-12] compared to men with CA ancestry. Accordingly, for AA men, the lifetime risk of developing PCa is 1 in 6, while that for CA men is 1 in 8. AA men are also greater than twice as likely to succumb to the disease compared with CA men as the PCa specific mortality in AA men is 1 in 23 whereas it is 1 in 42 in CA men [1, 2, 7].

In order to overcome the disparity that affects AA population negatively and to develop personalized therapeutic approaches, we need to identify and understand the factors that drive PCa tumor progression and metastasis in AA men. Over the years, a number of such interconnected factors including socioeconomic status, lifestyle and dietary

issues, problems with accessing healthcare have been identified as probable causes of this epidemiological disparity in PCa incidence and mortality [1, 2, 8]. Interestingly, several newer lines of evidence have also demonstrated genetic and biological variations among patients of different racial backgrounds. The androgen hormonal axis, the androgen receptor (AR), and its signaling pathway play critical roles in PCa progression [13]. Several aspects of the AR pathway have also been implicated in PCa associated racial differences [14-16]. However, in addition to androgens and AR signaling, the crosstalk between epithelial cells and cellular components of the tumor microenvironment (TME), such as mesenchymal stem cells, endothelial cells, fibroblasts/myofibroblasts, and immune cells also plays an integral role in PCa progression and metastasis [2,17]. The immune cells as well as the endothelial cells forming the blood vessels in the PCa TME, secrete growth factors and cytokines to induce PCa cell proliferation and spread [2, 17]. Increasing evidences now indicate that the TME components may also be a significant contributor to the racial disparity observed in PCa incidence, aggressiveness and clinical outcomes between AA and CA populations [2, 18-20]. Therefore, we have reviewed the pertinent data to discuss the potential contribution of the TME to the observed racial disparity associated with PCa (**Table 1**).

Table 1. Role of stromal cells in AA and CA PCa.

Cell type	Role in PCa	Differences in AA and CA PCa	References
Fibroblasts	<ul style="list-style-type: none"> • Secrete chemokines, cytokines, growth factors (brain derived neurotrophic factor and chemokines like CCL5, CXCL5, SDF1-alpha and soluble factors such as VEGF, bFGF, HGF) • Promote tumor growth and metastasis 	<ul style="list-style-type: none"> • Pro-inflammatory cytokines and growth factors [brain-derived neurotrophic factor (BDNF), VEGF, and fibroblast growth factor 7 (FGF7)] are significantly elevated in AA PCa • Higher expressions of myofibroblast activating markers [αSMA, vimentin, and FAP1] and mesenchymal stem cell marker, CD90, in cancer associated fibroblasts (CAFs) of AA PCa 	2,19
Immune cells	<ul style="list-style-type: none"> • Inflammation promotes initiation and progression 	<ul style="list-style-type: none"> • Increased lymphocytic infiltration in AA PCa tissues • Pro-inflammatory cytokines (interferon-alpha (IFNα), IFNγ, tumor necrosis factor-alpha (TNFα), and Interleukin 4 and Interleukin 13) are upregulated in PCa of AA men • Increased NK cell activity in AA PCa 	2, 28, 34-36
Endothelial Cells	<ul style="list-style-type: none"> • Form neovesels to support tumor growth and metastatic progression 	<ul style="list-style-type: none"> • Increased VEGF secretion in AA PCa • Higher MVD in AA PCa tissues 	2,19, 44, 50


2.0. Prostate Cancer Microenvironment

Prostate, a tubule-alveolar gland is primarily composed of prostatic epithelial cells surrounded by the stromal components [17, 21]. The gland has three distinct zones; peripheral, central, transition, and a mixed zone called the anterior fibro-muscular zone or stromal zone [17, 21, 22]. It is mainly composed of four major epithelial cell types- basal cells, neuroendocrine cells, epithelial stem/progenitor cells, and secretory luminal cells [17, 22]. The stroma consists primarily of fibroblasts, myofibroblasts, endothelial cells, immune cells, nerve cells and smooth muscle cells [17, 22].

The development and progression of PCa is a complex process and the disease is extremely heterogeneous from molecular, cellular and clinical standpoints [23]. In most cases, PCa originates in prostatic epithelial cells. Therefore, studies on PCa

development and progression have mainly focused on these cells [22, 23]. However, epithelial cells are not sole players contributing to PCa tumorigenesis; the stromal cells in the TME also play critical roles in PCa development and progression [2, 17, 24]. The crosstalk between the stroma and the epithelium is a major driver of PCa pathogenesis and disease progression [24, 25]. The interaction between the epithelial or cancer cells and the non-epithelial or stromal cells in PCa is mediated by a variety of paracrine factors secreted both by cancer cells as well as by the stromal cells [2, 25] (**Figure 1**). Several studies have emphasized the contribution of altered/reactive stromal microenvironment characterized by increase in the numbers of myofibroblasts and fibroblasts and significant decrease in the numbers of smooth muscle cells in tumorigenesis and progression of PCa [17, 25].

Figure 1: Interaction between PCa cells and the stroma (Created by BioRender)



Regarding the disproportionate burdens of PCa between AA and CA populations, while most studies have focused on genetic differences within different prostate tumor subtypes, emphasizing mostly on PCa cells, a handful of studies have also indicated how differences in PCa TME can affect tumor progression among men with different racial and ethnic backgrounds [18, 19]. Altered gene expression profiles of fibroblasts, immune cells and angiogenic components was noted between the TME of AA and CA men with PCa [18-20, 26-27]. In a study involving PCa samples from patients of AA and CA backgrounds, a total of 677 genes associated with 103 pathways were identified to be differentially expressed in the PCa TME [20]. Furthermore, pathway analysis and disease association studies have revealed a significant

difference in tumor inflammatory response and cytokine secretion between AA and CA patient samples [18, 20, 21, 28, 29]. The differences in TME of AA and CA PCa patients may account for the differences observed in tumor growth, progression and therapeutic response. In the following sections, we will therefore discuss the racial differences observed in three important cellular components of the TME in PCa: cancer associated fibroblasts (CAFs), immune cells and endothelial cells.

2.1. Fibroblasts

The stromal fibroblasts play a major role in normal prostate development as well as in PCa progression [2, 17, 25]. Cancer associated fibroblasts (CAFs) form a major component of TME and they actively communicate with PCa cells both via direct contact

and via soluble mediators such as chemokines, cytokines, growth factors secreted by both of the cell types [2, 17, 25, 30, 31]. This bidirectional communication between PCa cells and CAFs is crucial for tumor progression and metastasis. CAFs secrete growth factors like brain derived neurotrophic factor and chemokines like CCL5, CXCL5, SDF1-alpha and soluble factors such as VEGF, bFGF, HGF that promote PCa growth and progression [2, 19]. Studies have shown CAFs can differentially impact PCa progression in AA and CA patients. In a study where prostate fibroblasts from PCa specimens of AA and CA patients with similar clinicopathologic characteristics were isolated, it was noted that pro-inflammatory cytokines and growth factors [brain-derived neurotrophic factor (BDNF), VEGF, and fibroblast growth factor 7 (FGF7)] were significantly elevated in CAF isolated from AA PCa samples compared to CA PCa [19]. In addition, myofibroblast activating markers [α SMA, vimentin, and FAP1] and mesenchymal stem cell marker, CD90, showed significantly higher expressions in AA CAFs compared with CA CAFs [19]. With increased myofibroblastic components and presence of a population of mesenchymal-like cells (CD90+) it was inferred that AA-derived cells would show increased response to growth factors compared with CA-derived cells [19]. On the other hand, the expression of Caveolin1 (CAV1) that is a membrane-associated protein, whose expression in cancer cells increases with progression but loss in PCa stroma correlates with reduced relapse-free survival [19, 32, 33], was found to be lower in AA CAFs compared with CA CAFs. Upon exposure of PCa cells to conditioned media from fibroblasts isolated from AA and CA PCa patients, it was seen that there was increased proliferation and migration *in vitro* when PCa cells were exposed to conditioned media from AA prostate fibroblasts compared to CA prostate fibroblasts [19]. Furthermore, this study demonstrated that regardless of the racial

background of PCa cells, growth and/or proliferation of PCa cells was significantly increased when conditioned media from AA patients' fibroblasts was used (19). In addition, the study also reported an increased collagen deposition and myofibroblasts forming the 'reactive stroma' and elevated expression of fibroblast specific marker, tenascin-C, in the extracellular matrix (ECM) of AA PCa patients [19]. High expression of tenascin-C in CAFs is associated with poor prognosis in PCa [34]. Taken together; these data suggest that CAFs in AA PCa patients produce significantly higher levels of growth factors that enhance the tumorigenicity of PCa cells compared with CAFs in CA PCa patients.

2.2. Immune Cells

Although PCa is considered as a poorly immunogenic tumor, chronic inflammation has been consistently shown to be associated with the development and progression of the disease [35]. Immune cells form the cellular arm of inflammatory responses and presence of inflammatory cells in PCa TME is well documented. Only a few studies however have explored the immunological differences observed in the TME of AA and CA PCa. [36]. Very recently, it was reported that there is over-representation of immunogenic TME in AA PCa patients, with significantly higher inflammatory cytokines and lymphocytic infiltrates which increases the potential for better response to immunotherapy in these patients [37]. Studies have reported a significant difference in both the numbers and types of inflammatory cells and inflammatory responses between AA and CA PCa populations. Differences were noted between AA and CA PCa patients in expression of chronic inflammatory cytokines, such as interferon-alpha ($IFN\alpha$), $IFN\gamma$, tumor necrosis factor-alpha ($TNF\alpha$), Interleukin (IL) IL-1 β , IL 4, IL 6, IL 8 and IL 13. These pro-inflammatory cytokines show significant


upregulation in PCa of AA men [20, 38]. IL-6 promotes migration of cells and helps to evade apoptosis through STAT and PI3K pathways and is considered immunosuppressive as it helps to recruit myeloid derived suppressor cells (MDSC) to the TME [37, 39]. IL-8 activates neutrophil and plays a role in cell proliferation and invasion. Higher levels of IL-8 expression in PCa was associated with higher tumor grade but this association was comparable in AA and CA PCa [37, 40]. A recent study that was conducted using grade, stage matched AA and CA PCa, has reported an increased lymphocytic infiltration in AA PCa tissues compared to PCa tissues of CA origin [28]. Upon further analysis of the lymphocytic population, the study reported a higher presence of plasma cells in TME of AA PCa that correlated with IFN γ expression and increased inflammation observed in these tissues [28]. High expression of IgG was also noted in these AA PCa samples, which suggested more antibody secretion by these cells [28]. In addition, increased activity of NK cells, which primarily drives antibody dependent cellular toxicity, have been reported in AA PCa tissues compared to tissues from CA patient [28]. A different study also reported that AA PCa had higher expression of CD4+ and CD8+ T-cell markers in TME [38]. In contrast, there is also a report that indicated no difference in T-cell infiltration between AA and CA PCa but increased regulatory T-cells in AA PCa that correlated with disease recurrence [41]. Poor disease prognosis

associated with lymphocytic TME infiltrates may be due to their association with more aggressive tumors, or as the infiltrating T-cells were dysfunctional, or as were immunosuppressive regulatory T-cells [37, 42].

Macrophages comprise a major portion of the immune cells in the TME. M1 type or classically activated macrophages which are anti-tumorigenic and M2 type or alternatively activated macrophages which are pro-tumorigenic have been shown to be present in the PCa TME. In the TME, the tumor-associated macrophages (TAMs) are converted from a M1-type to the M2-type phenotype that secrete numerous growth factors, which influence diverse processes during PCa progression. The density and type of TAMs present in PCa thus provide prognostic information [2, 43]. AA PCa patients show increased TAM numbers compared to CA PCa patients as both CD68+ (M1), and CD163+ (M2) cells were significantly higher in AA PCa tissues [2].

A study investigating the role of inflammation and immune genes in AA PCa characterized 124 TME and immune response genes in AA PCa patients [44]. It was reported that 22% of total AAM patients showed adverse pathology features, high genomic risk (53%) and higher expressions of immune-response genes some of which along with their functions have been included in **Table 2**.

Table 2: Immune response genes elevated in AA PCa patients compared to CA PCa patients.

Gene Name	Expression in AA PCa patients	Role in cancer	References
Cluster of differentiation 2 (CD2)		Immunomodulatory in the TME; associated with delayed disease progression; enhances tumor immunogenicity and may improve response to immunotherapy.	44, 45

Cluster of differentiation 3 (CD3)	↑	Activates cytotoxic T cells (CD8+ naive T cells) and T helper cells (CD4+ naive T cells).	44, 46
Cluster of differentiation 4 (CD4)	↑	Immunosuppressive; may help in identifying patient subset that would benefit from immunotherapy.	44, 47, 48
Cluster of differentiation 45 (CD45)	↑	Regulates lymphocyte survival, cytokine responses, and TCR signaling; altered CD45 could result in severe combined immunodeficiency.	44, 49
Cluster of differentiation 96 (CD96)	↑	Inhibits function of CD8+ T cells; regulates NK cell effector function and cellular metastasis.	44, 50
C-C Motif Chemokine Ligand 5 (CCL5)	↑	Promotes angiogenesis and metastasis; increases drug resistance; promotes self-renewal of PCa cells.	44, 51
C-X-C Motif Chemokine Ligand 9 (CXCL9)	↑	Inhibits cytokine secretion from T cells; promotes PCa progression.	44, 52
C-X-C Motif Chemokine Ligand 10 (CXCL10)	↑	Increase infiltration of pre-adipocytes and TAMs in PCa TME; promotes migration and invasion of PCa cells.	44, 53
C-X-C Motif Chemokine Ligand 11 (CXCL11)	↑	Promotes PCa cell migration and invasion.	44, 54
Signal transducer and activator of transcription 1 (STAT1)	↑	Tumor suppressor in early PCa stages; promotes drug resistance.	44, 55
Indoleamine 2,3-dioxygenase 1 (IDO1)	↑	Mediates immunosuppression; associated with significantly worse clinical outcomes.	44,56
Matrix metalloproteinase 9 (MMP9)	↑	Promotes angiogenesis.	18, 57
Autocrine motility factor receptor (AMFR)	↑	Mediates AMF-mediated cell migration and metastasis.	18, 58

Taken together, the TME in PCa exhibits an immunosuppressive microenvironment and manifests a unique immune repertoire in AA population characterized by increased inflammatory mediators and significant enrichment of proinflammatory immune pathways creating a tumor supportive environment that negatively

associates with disease outcomes. However, a study also indicates that there is no significant association between inflammatory infiltrate and inflammation and the difference in PCa incidence and outcomes in different racial groups [59, 60]. Therefore, more studies are needed to draw a conclusion regarding

contribution of immune microenvironment to PCa associated racial disparity.

2.3. Endothelial Cells

In addition to the fibroblasts and immune cells, endothelial cells form a major cellular component of the TME. Endothelial cells form new blood vessels from existing vasculature by a process termed angiogenesis to meet the nutrient and oxygen requirements of the rapidly dividing cancer cells. Additionally, these cells by forming neovessels provide routes for dissemination of cancer cells to other parts of the body [61-67]. In order to propagate and form new blood vessels the endothelial cells in TME respond to growth factors secreted by cancer cells and cells in TME including endothelial cells themselves, such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF). PCa, like other solid tumors depends on angiogenesis and overexpression of proangiogenic factors like VEGF and FGF have been shown to be associated with poor PCa prognosis [65, 68-71].

VEGF is the most prominent cytokine regulating the process of angiogenesis [65, 70, 72, 73]. In PCa, the expressions of VEGF and/or its receptor VEGFR-2 are directly correlated to tumor Gleason grade, metastatic potential, and progression-free survival (PFS). In AA PCa TME increased VEGF secretion by fibroblasts may impact tumor angiogenesis [71]. Microvessel density (MVD) a surrogate marker assessing angiogenic response in tissues has been shown to be higher in PCa tissues collected from AA patients compared to patients with CA background. [2, 19]. These differences in expression of angiogenic factors and angiogenic response observed between PCa of AA and CA men could differentially influence PCa growth, metastasis and clinical outcomes in these two populations.

3.0. Clinical implications of the racially different tumor microenvironment composition in prostate cancer

TME in PCa patients with different racial backgrounds show prominent genetic variability which influences their ability to synthesize, secrete and, respond to growth factors which results in differential growth, progression and therapeutic responses [2, 17, 19, 20, 24]. With the differences observed in TME, it is more likely that AA PCa patients may respond differently to different therapeutic strategies. Recent evidence indicates that even though immunotherapy has not been very successful in PCa, AA patients might benefit from it due to the differences in the immune landscape. In the PROCEED (NCT01306890) trial for receiving immunotherapy with sipuleucel-T for metastatic castration resistant prostate cancer (mCRPC), AA PCa patients showed a higher survival advantage than CA PCa patients [74]. In the PSA-matched set, median overall survival (OS) for AA patients was 35.3 and that for CA patients was 25.8 months and in the all patient set, OS of AA patients was 35.2 months as compared to 29.9 months for CA patients. mCRPC AA patients with lower baseline PSA showed even longer OS of over 4.5 years compared to 2.8 years for CA patients. The better response to immunotherapy shown by AA PCa patients proves the differences in immune response in AA and CA PCa patients [35]. AA PCa patients have been predicted to have higher response score to DNA damage and alkylating agent-based chemotherapy whereas CA PCa has a higher response score to microtubule-based chemotherapy [44]. Other studies have reported that the regular use of aspirin can significantly reduce both the risk of developing metastatic PCa and disease recurrence in AAM [75, 76] by targeting the pro-inflammatory cyclooxygenase/thromboxane A₂ pathway [77]. Evidence also suggests reduced mortality due to PCa in AAM

using aspirin [78]. Furthermore, TME facilitates therapeutic resistance by modification of stromal components to promote invasion, angiogenesis, and metastases. Patient response to therapy depends strongly on activation of tumor stroma. The presence of myofibroblasts, that show higher expressions in AA patients than CA patients, predicts biochemical recurrence in PCa patients [79]. CAFs were also shown to induce chemoresistance through induction of EMT [80]. Interaction of TAMs and cancer stem cells (CSCs) can result in resistance to ADT therapy. CSCs help in TAM remodeling and TAMs promote the stem-like properties of CSCs and drug resistance by acting through the IL-6/STAT3 signaling pathway [81].

4.0. Conclusion and future perspective

The TME is a key contributor to PCa progression and determinant of clinical outcomes. The stromal cells and the extracellular milieu of the TME regulate the plasticity of the phenotypic traits of PCa cells. The interaction between PCa cells and surrounding TME components (immune, vascular, and stromal) are therefore being studied extensively to understand its broader role in pathobiology and disease outcomes [2, 17, 19, 20, 24] using traditional *in vitro* and *in vivo* experiments and recently by fluorescence-activated cell sorting or laser microdissection with RNA sequencing and spatial transcriptomics [82, 83, 84]. The recent technique of multiplex immunofluorescence (mIF) with tyramide signal amplification helps to gather maximum information from a single tissue section with accurate classification of the TME cell population [85]. Use of single-cell RNA transcriptome sequencing (scRNA-seq) can indicate the cell heterogeneity and help to analyze cellular interactions [82]. The use of these techniques will further help to identify the role of the modulated

genes in individual TME components of AA and CA PCa.

Data related to the role of TME in race-associated cancer health disparity has only recently begun to emerge in prostate and other cancers. Further studies involving larger datasets from diverse patient populations would provide more strengths to TME differences and their association with clinical outcomes and clinicopathologic progression of cancer. Similarly, more efforts should also be made to determine the exact contribution of TME to differential PCa progression using appropriate experimental models and delineate the underlying molecular mechanisms. Unlike the cancer cells, cells of the TME are genetically stable, which make them attractive targets for cancer management (prevention and treatment) and to reduce the risk of acquiring therapy resistance leading to treatment failure and recurrence. A better understanding of the role of the TME will also help in the development of race-specific biomarkers and therapeutic targets leading to personalized approaches for risk prediction, diagnosis, monitoring, and management of PCa.

Acknowledgments

Authors are supported by funding from NIH/NCI (R01CA231925 to SS) and USA Health Mitchell Cancer Institute, University of South Alabama.

Conflicts of interest

The authors declare that they have no conflicts of interest with the contents of this article.

Authors' contributions

Conception and design: DC. Initial manuscript writing: SG, CS, and DC. Review and revision of the manuscript: SG, CS, SS, APS and DC.

REFERENCES

- Siegel, R.L., Miller, K.D., Fuchs, H.E., and Jemal, A. (2021). Cancer Statistics, 2021. *CA Cancer J Clin.*71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12. Erratum in: *CA Cancer J Clin.* 71(4):359. PMID: 33433946.
- Kakarla, M., ChallaSivaKanaka, S., Hayward, S. W., and Franco, O. E. (2021). Race as a Contributor to Stromal Modulation of Tumor Progression. *Cancers*, 13(11), 2656. <https://doi.org/10.3390/cancers13112656>
- Badal, S., Aiken, W., Morrison, B., Valentine, H., Bryan, S., Gachii, A., and Ragin, C. (2020). Disparities in prostate cancer incidence and mortality rates: Solvable or not?. *The Prostate*, 80(1), 3–16. <https://doi.org/10.1002/pros.23923>
- Johnson, J. R., Woods-Burnham, L., Hooker, S. E., Jr, Batai, K., and Kittles, R. A. (2021). Genetic Contributions to Prostate Cancer Disparities in Men of West African Descent. *Frontiers in oncology*, 11, 770500. <https://doi.org/10.3389/fonc.2021.770500>
- Taitt H. E. (2018). Global Trends and Prostate Cancer: A Review of Incidence, Detection, and Mortality as Influenced by Race, Ethnicity, and Geographic Location. *American journal of men's health*, 12(6), 1807–1823. <https://doi.org/10.1177/1557988318798279>
- Marima, R., Hull, R., Mathabe, K., Setlai, B., Batra, J., Sartor, O., Mehrotra, R., and Dlamini, Z. (2021). Prostate cancer racial, socioeconomic, geographic disparities: targeting the genomic landscape and splicing events in search for diagnostic, prognostic and therapeutic targets. *American journal of cancer research*, 11(4), 1012–1030.
- Siegel, D. A., O'Neil, M. E., Richards, T. B., Dowling, N. F., and Weir, H. K. (2020). Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity - United States, 2001-2017. *MMWR. Morbidity and mortality weekly report*, 69(41), 1473–1480. <https://doi.org/10.15585/mmwr.mm6941a1>
- Bhardwaj, A., Srivastava, S. K., Khan, M. A., Prajapati, V. K., Singh, S., Carter, J. E., and Singh, A. P. (2017). Racial disparities in prostate cancer: a molecular perspective. *Frontiers in bioscience (Landmark edition)*, 22, 772–782. <https://doi.org/10.2741/4515>
- Tsodikov, A., Gulati, R., de Carvalho, T. M., Heijnsdijk, E., Hunter-Merrill, R. A., Mariotto, A. B., de Koning, H. J., and Etzioni, R. (2017). Is prostate cancer different in black men? Answers from 3 natural history models. *Cancer*, 123(12), 2312–2319. <https://doi.org/10.1002/cncr.30687>
- Cotter, M. P., Gern, R. W., Ho, G. Y., Chang, R. Y., and Burk, R. D. (2002). Role of family history and ethnicity on the mode and age of prostate cancer presentation. *The Prostate*, 50(4), 216–221. <https://doi.org/10.1002/pros.10051>
- Lindquist, K. J., Paris, P. L., Hoffmann, T. J., Cardin, N. J., Kazma, R., Mefford, J. A., Simko, J. P., Ngo, V., Chen, Y., Levin, A. M., Chitale, D., Helfand, B. T., Catalona, W. J., Rybicki, B. A., and Witte, J. S. (2016). Mutational Landscape of Aggressive Prostate Tumors in African American Men. *Cancer research*, 76(7), 1860–1868. <https://doi.org/10.1158/0008-5472.CAN-15-1787>
- Tan, S. H., Petrovics, G., and Srivastava, S. (2018). Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities. *International journal of molecular sciences*, 19(4), 1255. <https://doi.org/10.3390/ijms19041255>
- Lonergan, P. E., and Tindall, D. J. (2011). Androgen receptor signaling in prostate cancer development and progression. *Journal of carcinogenesis*, 10, 20. <https://doi.org/10.4103/1477-3163.83937>
- Gaston, K. E., Kim, D., Singh, S., Ford, O. H., 3rd, and Mohler, J. L. (2003). Racial differences in androgen receptor protein expression in men with clinically localized prostate cancer. *The Journal of urology*, 170(3), 990–993. <https://doi.org/10.1097/01.ju.0000079761.56154.e5>
- Crawford E. D. (2003). Epidemiology of prostate cancer. *Urology*, 62(6 Suppl 1), 3–12. <https://doi.org/10.1016/j.urology.2003.10.013>
- Karakas, C., Wang, C., Deng, F., Huang, H., Wang, D., and Lee, P. (2017). Molecular mechanisms involving prostate cancer racial disparity. *American journal of clinical and experimental urology*, 5(3), 34–48.
- Josson, S., Matsuoka, Y., Chung, L. W., Zhau, H. E., and Wang, R. (2010). Tumor-stroma co-evolution in prostate cancer progression and metastasis. *Seminars in cell & developmental biology*, 21(1), 26–32. <https://doi.org/10.1016/j.semcd.2009.11.016>
- Wallace, T. A., Prueitt, R. L., Yi, M., Howe, T. M., Gillespie, J. W., Yfantis, H. G., Stephens, R. M., Caporaso, N. E., Loffredo, C. A., and Ambis, S. (2008). Tumor immunobiological differences in prostate cancer between African-American and European-American men. *Cancer research*, 68(3), 927–936. <https://doi.org/10.1158/0008-5472.CAN-07-2608>
- Gillard, M., Javier, R., Ji, Y., Zheng, S. L., Xu, J., Brendler, C. B., Crawford, S. E., Pierce, B. L., Griendl, D., and Franco, O. E. (2018). Elevation of Stromal-Derived Mediators of Inflammation Promote Prostate Cancer Progression in African-American Men. *Cancer research*, 78(21), 6134–6145. <https://doi.org/10.1158/0008-5472.CAN-17-3810>
- Kinseth, M. A., Jia, Z., Rahmatpanah, F., Sawyers, A., Sutton, M., Wang-Rodriguez, J., Mercola, D., and McGuire, K. L. (2014). Expression differences between African American and Caucasian prostate cancer tissue reveals that stroma

- is the site of aggressive changes. *International journal of cancer*, 134(1), 81–91. <https://doi.org/10.1002/ijc.28326>
21. Aaron, L., Franco, O. E., and Hayward, S. W. (2016). Review of Prostate Anatomy and Embryology and the Etiology of Benign Prostatic Hyperplasia. *The Urologic clinics of North America*, 43(3), 279–288. <https://doi.org/10.1016/j.ucl.2016.04.012>
 22. Yu, J., Fulcher, A. S., Winks, S. G., Turner, M. A., Clayton, R. D., Brooks, M., and Li, S. (2017). Diagnosis of typical and atypical transition zone prostate cancer and its mimics at multiparametric prostate MRI. *The British journal of radiology*, 90(1073), 20160693. <https://doi.org/10.1259/bjr.20160693>
 23. Datta, D., Aftabuddin, M., Gupta, D. K., Raha, S., and Sen, P. (2016). Human Prostate Cancer Hallmarks Map. *Scientific reports*, 6, 30691. <https://doi.org/10.1038/srep30691>
 24. Shiao, S. L., Chu, G. C., & Chung, L. W. (2016). Regulation of prostate cancer progression by the tumor microenvironment. *Cancer letters*, 380(1), 340–348. <https://doi.org/10.1016/j.canlet.2015.12.022>
 25. Bonollo, F., Thalmann, G. N., Kruihof-de Julio, M., and Karkampouna, S. (2020). The Role of Cancer-Associated Fibroblasts in Prostate Cancer Tumorigenesis. *Cancers*, 12(7), 1887. <https://doi.org/10.3390/cancers12071887>
 26. Reams, R. R., Agrawal, D., Davis, M. B., Yoder, S., Odedina, F. T., Kumar, N., Higginbotham, J. M., Akinremi, T., Suther, S., and Soliman, K. F. (2009). Microarray comparison of prostate tumor gene expression in African-American and Caucasian American males: a pilot project study. *Infectious agents and cancer*, 4 Suppl 1(Suppl 1), S3. <https://doi.org/10.1186/1750-9378-4-S1-S3>
 27. Yuan, J., Kensler, K. H., Hu, Z., Zhang, Y., Zhang, T., Jiang, J., Xu, M., Pan, Y., Long, M., Montone, K. T., Tanyi, J. L., Fan, Y., Zhang, R., Hu, X., Rebbeck, T. R., and Zhang, L. (2020). Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry. *PLoS genetics*, 16(2), e1008641. <https://doi.org/10.1371/journal.pgen.1008641>
 28. Weiner, A. B., Vidotto, T., Liu, Y., Mendes, A. A., Salles, D. C., Faisal, F. A., Murali, S., McFarlane, M., Imada, E. L., Zhao, X., Li, Z., Davicioni, E., Marchionni, L., Chinnaiyan, A. M., Freedland, S. J., Spratt, D. E., Wu, J. D., Lotan, T. L., and Schaeffer, E. M. (2021). Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. *Nature communications*, 12(1), 935. <https://doi.org/10.1038/s41467-021-21245-w>
 29. Rahmatpanah, F., Robles, G., Lilly, M., Keane, T., Kumar, V., Mercola, D., Randhawa, P., and McClelland, M. (2021). RNA expression differences in prostate tumors and tumor-adjacent stroma between Black and White Americans. *Oncotarget*, 12(15), 1457–1469. <https://doi.org/10.18632/oncotarget.28024>
 30. Franco, O. E., Shaw, A. K., Strand, D. W., and Hayward, S. W. (2010). Cancer associated fibroblasts in cancer pathogenesis. *Seminars in cell & developmental biology*, 21(1), 33–39. <https://doi.org/10.1016/j.semcdb.2009.10.010>
 31. Chiarugi, P., Paoli, P., & Cirri, P. (2014). Tumor microenvironment and metabolism in prostate cancer. *Seminars in oncology*, 41(2), 267–280. <https://doi.org/10.1053/j.seminoncol.2014.03.004>
 32. Ayala, G., Morello, M., Frolov, A., You, S., Li, R., Rosati, F., Bartolucci, G., Danza, G., Adam, R. M., Thompson, T. C., Lisanti, M. P., Freeman, M. R., and Vizio, D. D. (2013). Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression. *The Journal of pathology*, 231(1), 77–87. <https://doi.org/10.1002/path.4217>
 33. Chen, D., and Che, G. (2014). Value of caveolin-1 in cancer progression and prognosis: Emphasis on cancer-associated fibroblasts, human cancer cells and mechanism of caveolin-1 expression (Review). *Oncology letters*, 8(4), 1409–1421. <https://doi.org/10.3892/ol.2014.2385>
 34. Ni, W. D., Yang, Z. T., Cui, C. A., Cui, Y., Fang, L. Y., and Xuan, Y. H. (2017). Tenascin-C is a potential cancer-associated fibroblasts marker and predicts poor prognosis in prostate cancer. *Biochemical and biophysical research communications*, 486(3), 607–612. <https://doi.org/10.1016/j.bbrc.2017.03.021>
 35. Strasner, A., & Karin, M. (2015). Immune Infiltration and Prostate Cancer. *Frontiers in oncology*, 5, 128. <https://doi.org/10.3389/fonc.2015.00128>
 36. King Thomas, J., Mir, H., Kapur, N., & Singh, S. (2019). Racial Differences in Immunological Landscape Modifiers Contributing to Disparity in Prostate Cancer. *Cancers*, 11(12), 1857. <https://doi.org/10.3390/cancers11121857>
 37. Sentana-Lledo, D., Sartor, O., Balk, S. P., & Einstein, D. J. (2022). Immune mechanisms behind prostate cancer in men of African ancestry: A review. *The Prostate*, 10.1002/pros.24333. Advance online publication. <https://doi.org/10.1002/pros.24333>
 38. Awasthi, S., Berglund, A., Abraham-Miranda, J., Rounbehler, R. J., Kensler, K., Serna, A., Vidal, A., You, S., Freeman, M. R., Davicioni, E., Liu, Y., Karnes, R. J., Klein, E. A., Den, R. B., Trock, B. J., Campbell, J. D., Einstein, D. J., Gupta, R., Balk, S., Lal, P., ... Yamoah, K. (2021). Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. *Clinical cancer research : an official journal of the American Association for Cancer*

- Research*, 27(1), 320–329. <https://doi.org/10.1158/1078-0432.CCR-20-2925>
39. Wu, C. T., Hsieh, C. C., Lin, C. C., Chen, W. C., Hong, J. H., & Chen, M. F. (2012). Significance of IL-6 in the transition of hormone-resistant prostate cancer and the induction of myeloid-derived suppressor cells. *Journal of molecular medicine (Berlin, Germany)*, 90(11), 1343–1355. <https://doi.org/10.1007/s00109-012-0916-x>
 40. Maynard, J. P., Ertunc, O., Kulac, I., Baena-Del Valle, J. A., De Marzo, A. M., & Sfanos, K. S. (2020). IL8 Expression Is Associated with Prostate Cancer Aggressiveness and Androgen Receptor Loss in Primary and Metastatic Prostate Cancer. *Molecular cancer research : MCR*, 18(1), 153–165. <https://doi.org/10.1158/1541-7786.MCR-19-0595>
 41. Kaur, H. B., Guedes, L. B., Lu, J., Maldonado, L., Reitz, L., Barber, J. R., De Marzo, A. M., Tosoian, J. J., Tomlins, S. A., Schaeffer, E. M., Joshi, C. E., Sfanos, K. S., & Lotan, T. L. (2018). Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer. *Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc*, 31(10), 1539–1552. <https://doi.org/10.1038/s41379-018-0083-x>
 42. Vitkin, N., Nersesian, S., Siemens, D. R., & Koti, M. (2019). The Tumor Immune Contexture of Prostate Cancer. *Frontiers in immunology*, 10, 603. <https://doi.org/10.3389/fimmu.2019.00603>
 43. Wang, Y., Freedman, J. A., Liu, H., Moorman, P. G., Hyslop, T., George, D. J., Lee, N. H., Patierno, S. R., and Wei, Q. (2017). Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. *International journal of cancer*, 141(4), 731–743. <https://doi.org/10.1002/ijc.30787>
 44. Rayford, W., Beksac, A. T., Alger, J., Alshalalfa, M., Ahmed, M., Khan, I., Falagario, U. G., Liu, Y., Davicioni, E., Spratt, D. E., Schaeffer, E. M., Feng, F. Y., Mahal, B., Nguyen, P. L., Den, R. B., Greenberger, M. D., Bradley, R., Watson, J. M., Beamer, M., Stamatakis, L., ... Tewari, A. K. (2021). Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. *Communications biology*, 4(1), 670. <https://doi.org/10.1038/s42003-021-02140-y>
 45. Chen, Y., Meng, Z., Zhang, L., & Liu, F. (2021). CD2 Is a Novel Immune-Related Prognostic Biomarker of Invasive Breast Carcinoma That Modulates the Tumor Microenvironment. *Frontiers in immunology*, 12, 664845. <https://doi.org/10.3389/fimmu.2021.664845>
 46. Bühler, P., Wolf, P., Gierschner, D., Schaber, I., Katzenwadel, A., Schultze-Seemann, W., Wetterauer, U., Tacke, M., Swamy, M., Schamel, W. W., & Elsässer-Beile, U. (2008). A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. *Cancer immunology, immunotherapy : CII*, 57(1), 43–52. <https://doi.org/10.1007/s00262-007-0348-6>
 47. Miller, A. M., Lundberg, K., Ozenci, V., Banham, A. H., Hellström, M., Egevad, L., & Pisa, P. (2006). CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. *Journal of immunology (Baltimore, Md. : 1950)*, 177(10), 7398–7405. <https://doi.org/10.4049/jimmunol.177.10.7398>
 48. Kwek, S. S., Lewis, J., Zhang, L., Weinberg, V., Greaney, S. K., Harzstark, A. L., Lin, A. M., Ryan, C. J., Small, E. J., & Fong, L. (2015). Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. *Cancer immunology research*, 3(9), 1008–1016. <https://doi.org/10.1158/2326-6066.CIR-14-0227>
 49. Al Barashdi, M. A., Ali, A., McMullin, M. F., & Mills, K. (2021). Protein tyrosine phosphatase receptor type C (PTPRC or CD45). *Journal of clinical pathology*, 74(9), 548–552. <https://doi.org/10.1136/jclinpath-2020-206927>
 50. Mittal, D., Lepletier, A., Madore, J., Aguilera, A. R., Stannard, K., Blake, S. J., Whitehall, V., Liu, C., Bettington, M. L., Takeda, K., Long, G. V., Scolyer, R. A., Lan, R., Siemers, N., Korman, A., Teng, M., Johnston, R. J., Dougall, W. C., & Smyth, M. J. (2019). CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function. *Cancer immunology research*, 7(4), 559–571. <https://doi.org/10.1158/2326-6066.CIR-18-0637>
 51. Huang, R., Guo, L., Gao, M., Li, J., & Xiang, S. (2021). Research Trends and Regulation of CCL5 in Prostate Cancer. *OncoTargets and therapy*, 14, 1417–1427. <https://doi.org/10.2147/OTT.S279189>
 52. Tan, S., Wang, K., Sun, F., Li, Y., & Gao, Y. (2018). CXCL9 promotes prostate cancer progression through inhibition of cytokines from T cells. *Molecular Medicine Reports*, 18, 1305–1310.
 53. Gwak, J., Jeong, H., Lee, K., Shin, J. Y., Sim, T., Na, J., Kim, J., & Ju, B. G. (2020). SFMBT2-Mediated Infiltration of Preadipocytes and TAMs in Prostate Cancer. *Cancers*, 12(9), 2718. <https://doi.org/10.3390/cancers12092718>
 54. Wang, Y., Xu, H., Si, L., Li, Q., Zhu, X., Yu, T., & Gang, X. (2018). MiR-206 inhibits proliferation and migration of prostate cancer cells by targeting CXCL11. *The Prostate*, 78(7), 479–490. <https://doi.org/10.1002/pros.23468>
 55. Patterson, S. G., Wei, S., Chen, X., Sallman, D. A., Gilvary, D. L., Zhong, B., Pow-Sang, J., Yeatman, T., & Djeu, J. Y. (2006). Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. *Oncogene*, 25(45), 6113–6122. <https://doi.org/10.1038/sj.onc.1209632>

56. Nayak-Kapoor, A., Hao, Z., Sadek, R., Dobbins, R., Marshall, L., Vahanian, N. N., Jay Ramsey, W., Kennedy, E., Mautino, M. R., Link, C. J., Lin, R. S., Royer-Joo, S., Liang, X., Salphati, L., Morrissey, K. M., Mahrus, S., McCall, B., Pirzkall, A., Munn, D. H., Janik, J. E., ... Khleif, S. N. (2018). Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors. *Journal for immunotherapy of cancer*, 6(1), 61. <https://doi.org/10.1186/s40425-018-0351-9>
57. Larsson, P., Syed Khaja, A. S., Semenas, J., Wang, T., Sarwar, M., Dizzeyi, N., Simoulis, A., Hedblom, A., Wai, S. N., Ødum, N., & Persson, J. L. (2020). The functional interlink between AR and MMP9/VEGF signaling axis is mediated through PIP5K1α/pAKT in prostate cancer. *International journal of cancer*, 146(6), 1686–1699. <https://doi.org/10.1002/ijc.32607>
58. Huang, B., Raz, A. (1995). Differential expression of autocrine motility factor receptor (AMFR) mRNA in normal and cancer cells detected by in situ hybridization. *Cell Res* (5), 221–234. <https://doi.org/10.1038/cr.1995.21>
59. Dovey, Z. S., Nair, S. S., Chakravarty, D., and Tewari, A. K. (2021). Racial disparity in prostate cancer in the African American population with actionable ideas and novel immunotherapies. *Cancer reports (Hoboken, N.J.)*, 4(5), e1340. <https://doi.org/10.1002/cnr2.1340>
60. Vidal, A. C., Chen, Z., Howard, L. E., Moreira, D. M., Castro-Santamaria, R., Andriole, G. L., Taioli, E., Fowke, J. H., Knudsen, B., Drake, C. G., Nickel, J. C., and Freedland, S. J. (2016). Racial differences in prostate inflammation: results from the REDUCE study. *Oncotarget*, 8(42), 71393–71399. <https://doi.org/10.18632/oncotarget.10690>
61. Folkman J. (1990). What is the evidence that tumors are angiogenesis dependent?. *Journal of the National Cancer Institute*, 82(1), 4–6. <https://doi.org/10.1093/jnci/82.1.4>
62. Carmeliet, P., and Jain, R. K. (2000). Angiogenesis in cancer and other diseases. *Nature*, 407(6801), 249–257. <https://doi.org/10.1038/35025220>
63. Dvorak H. F. (2002). Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 20(21), 4368–4380. <https://doi.org/10.1200/JCO.2002.10.088>
64. Ferrara, N., Gerber, H. P., and LeCouter, J. (2003). The biology of VEGF and its receptors. *Nature medicine*, 9(6), 669–676. <https://doi.org/10.1038/nm0603-669>
65. Sarkar, C., Goswami, S., Basu, S., and Chakroborty, D. (2020). Angiogenesis Inhibition in Prostate Cancer: An Update. *Cancers*, 12(9), 2382. <https://doi.org/10.3390/cancers12092382>
66. Chakroborty, D., Sarkar, C., Basu, B., Dasgupta, P. S., and Basu, S. (2009). Catecholamines regulate tumor angiogenesis. *Cancer research*, 69(9), 3727–3730. <https://doi.org/10.1158/0008-5472.CAN-08-4289>
67. Sarkar, C., Chakroborty, D., and Basu, S. (2013). Neurotransmitters as regulators of tumor angiogenesis and immunity: the role of catecholamines. *Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology*, 8(1), 7–14. <https://doi.org/10.1007/s11481-012-9395-7>
68. Picus, J., Halabi, S., Rini, B., Vogelzang, N., Whang, Y., Kaplan, E., Kelly, W., and Small, E. (2003). The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): Initial results Of CALGB 90006 (abstract 1578). *Proc Am Soc Oncol*. 22: 393.
69. Retter, A. S., Figg, W. D., and Dahut, W. L. (2003). The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer. *Clinical prostate cancer*, 2(3), 153–159. <https://doi.org/10.3816/cgc.2003.n.023>
70. Lara, P. N., Jr, Twardowski, P., and Quinn, D. I. (2004). Angiogenesis-targeted therapies in prostate cancer. *Clinical prostate cancer*, 3(3), 165–173. <https://doi.org/10.3816/cgc.2004.n.027>
71. Loblaw, D. A., Mendelson, D. S., Talcott, J. A., Virgo, K. S., Somerfield, M. R., Ben-Josef, E., Middleton, R., Porterfield, H., Sharp, S. A., Smith, T. J., Taplin, M. E., Vogelzang, N. J., Wade, J. L., Jr, Bennett, C. L., Scher, H. I., and American Society of Clinical Oncology (2004). American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*, 22(14), 2927–2941. <https://doi.org/10.1200/JCO.2004.04.579>
72. Nicholson, B., Gulding, K., Conaway, M., Wedge, S. R., and Theodorescu, D. (2004). Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 10(24), 8728–8734. <https://doi.org/10.1158/1078-0432.CCR-04-0902>
73. Melegh, Z., and Oltean, S. (2019). Targeting Angiogenesis in Prostate Cancer. *International journal of molecular sciences*, 20(11), 2676. <https://doi.org/10.3390/ijms20112676>
74. Sartor, O., Armstrong, A. J., Ahaghotu, C., McLeod, D. G., Cooperberg, M. R., Penson, D. F., Kantoff, P. W., Vogelzang, N. J., Hussain, A., Pieczonka, C. M., Shore, N. D., Quinn, D. I., Small, E. J., Heath, E. I., Tutrone, R. F., Schellhammer, P. F., Harmon, M., Chang, N. N., Sheikh, N.

- A., Brown, B., ... Higano, C. S. (2020). Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. *Prostate cancer and prostatic diseases*, 23(3), 517–526. <https://doi.org/10.1038/s41391-020-0213-7>
75. Smith, C. J., Dorsey, T. H., Tang, W., Jordan, S. V., Loffredo, C. A., & Ambs, S. (2017). Aspirin Use Reduces the Risk of Aggressive Prostate Cancer and Disease Recurrence in African-American Men. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, 26(6), 845–853. <https://doi.org/10.1158/1055-9965.EPI-16-1027>
76. Osborn, V. W., Chen, S. C., Weiner, J., Schwartz, D., & Schreiber, D. (2016). Impact of aspirin on clinical outcomes for African American men with prostate cancer undergoing radiation. *Tumori*, 102(1), 65–70. <https://doi.org/10.5301/tj.5000424>
77. Lucotti, S., Cerutti, C., Soyer, M., Gil-Bernabé, A. M., Gomes, A. L., Allen, P. D., Smart, S., Markelc, B., Watson, K., Armstrong, P. C., Mitchell, J. A., Warner, T. D., Ridley, A. J., & Muschel, R. J. (2019). Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2. *The Journal of clinical investigation*, 129(5), 1845–1862. <https://doi.org/10.1172/JCI121985>
78. Tang, W., Fowke, J. H., Hurwitz, L. M., Steinwandel, M., Blot, W. J., & Ambs, S. (2021). Aspirin Use and Prostate Cancer among African-American Men in the Southern Community Cohort Study. *Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology*, 30(3), 539–544. <https://doi.org/10.1158/1055-9965.EPI-19-0792>
79. Ayala, G., Tuxhorn, J. A., Wheeler, T. M., Frolov, A., Scardino, P. T., Otori, M., Wheeler, M., Spitler, J., & Rowley, D. R. (2003). Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 9(13), 4792–4801.
80. Fiori, M. E., Di Franco, S., Villanova, L., Bianca, P., Stassi, G., & De Maria, R. (2019). Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. *Molecular cancer*, 18(1), 70. <https://doi.org/10.1186/s12943-019-0994-2>
81. Huang, H., Wang, C., Liu, F., Li, H. Z., Peng, G., Gao, X., Dong, K. Q., Wang, H. R., Kong, D. P., Qu, M., Dai, L. H., Wang, K. J., Zhou, Z., Yang, J., Yang, Z. Y., Cheng, Y. Q., Tian, Q. Q., Liu, D., Xu, C. L., Xu, D. F., ... Sun, Y. H. (2018). Reciprocal Network between Cancer Stem-Like Cells and Macrophages Facilitates the Progression and Androgen Deprivation Therapy Resistance of Prostate Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 24(18), 4612–4626. <https://doi.org/10.1158/1078-0432.CCR-18-0461>
82. Ahmed, R., Zaman, T., Chowdhury, F., Mraiche, F., Tariq, M., Ahmad, I. S., & Hasan, A. (2022). Single-Cell RNA Sequencing with Spatial Transcriptomics of Cancer Tissues. *International journal of molecular sciences*, 23(6), 3042. <https://doi.org/10.3390/ijms23063042>
83. Mangiola, S., McCoy, P., Modrak, M., Souza-Fonseca-Guimaraes, F., Blashki, D., Stuchbery, R., Keam, S. P., Kerger, M., Chow, K., Nasa, C., Le Page, M., Lister, N., Monard, S., Peters, J., Dundee, P., Williams, S. G., Costello, A. J., Neeson, P. J., Pal, B., Huntington, N. D., ... Hovens, C. M. (2021). Transcriptome sequencing and multi-plex imaging of prostate cancer microenvironment reveals a dominant role for monocytic cells in progression. *BMC cancer*, 21(1), 846. <https://doi.org/10.1186/s12885-021-08529-6>
84. Zhu, S., Qing, T., Zheng, Y., Jin, L., & Shi, L. (2017). Advances in single-cell RNA sequencing and its applications in cancer research. *Oncotarget*, 8(32), 53763–53779. <https://doi.org/10.18632/oncotarget.17893>
85. Hernandez, S., Rojas, F., Laberiano, C., Lazcano, R., Wistuba, I., & Parra, E. R. (2021). Multiplex Immunofluorescence Tyramide Signal Amplification for Immune Cell Profiling of Paraffin-Embedded Tumor Tissues. *Frontiers in molecular biosciences*, 8, 667067. <https://doi.org/10.3389/fmolb.2021.667067>